Authors


Nicholas A. Kozauer, MD

Latest:

Depression in Patients With Alzheimer Dementia

Alzheimer dementia (AD) represents a profound global health concern. By the year 2050, the prevalence of AD in the United States is expected to reach 15 million. At present, there are 4.5 million cases in the United States, which equals an estimated cost of $100 billion each year in medical and family expenses.


Nicholas Demartinis, MD

Latest:

The Effects of Antidepressants on Sleep

Knowledge of how different antidepressants are likely to affect parameters of sleep can provide an important basis for selecting an appropriate antidepressant drug among the roughly 2 dozen marketed options to meet the needs of depressed patients.


Nicholas L. Salsman, PhD

Latest:

Understanding the Usefulness of Psychosocial Interventions for Personality Disorders

An examination of recent research on psychosocial treatments for personality disorders, including randomized controlled trials and empirically supported therapies as well as dialectical behavior therapy.


Nicholas Pediaditakis, MD

Latest:

The Dog That Did Not Bark

Some thoughts on the pathogenesis and persistence of prevalence of schizophrenia and bipolar affective disorder in view of current discoveries.


Nick C. Mellos, MD

Latest:

A Risk Stratification Approach to Alcohol Detoxification

The challenges of identifying patients at risk for alcohol withdrawal have been found to be mitigated by the development of a Risk Stratification Questionnaire, now being adopted by the VA regionally throughout New England. More in this video.


Nick Kanas, MD

Latest:

Psychiatric Issues in Space

The many potential stressors for astronauts during space missions present unique and fascinating 21st century psychiatric and psychological issues.


Nick Phelps

Latest:

A Word From Sandy Hook

It has become clear over the last couple of days that Sandy Hook Elementary School and Newtown have become an area of great concern locally, nationally, and internationally. We as a world community need to go through a grieving process that includes this type of sharing, especially for parents out there.


Nick Thomarios, MD

Latest:

Atypical Antipsychotics for Children and Adolescents With Schizophrenia-Spectrum Disorders

Although the onset of psychotic symptoms before the age of 13 years is exceedingly rare, the incidence of schizophrenia rises sharply after the onset of puberty.1 Only 1% of the population has schizophrenia and 30% of these patients experience an onset of psychotic symptoms by age 18 years.2-8 The period that precedes the onset of frank psychotic symptoms (ie, the prodromal phase) has not been well characterized in early-onset schizophrenia-spectrum disorders (EOSS), but retrospective reports have shown that symptoms include high levels of depression and anxiety, emerging cognitive and social deficits, unusual thought content, and (not infrequently) school failure.


Nicolas Badre, MD

Latest:

Abdicated Authority: How We Fail Conservatees

How can we ensure an accountable, effective, and limited conservatorship system? Here are some actionable concepts.


Nicole B. Washington, DO

Latest:

QTc Prolongation Associated With Psychotropics: Therapeutic Considerations

A focus on QTc monitoring in patients receiving psychotropics, especially when multiple medications are prescribed.


Nicole Braida, MD

Latest:

The Link Between Immune System Dysregulation and Schizophrenia

On the wide range of symptoms in schizophrenia, including alterations of the dopaminergic and/or glutamatergic systems, abnormal neurodevelopment, and the theory of immune system imbalance.


Nicole Charder, MD

Latest:

Heatstroke and Psychiatric Patients

A variety of commonly used psychiatric medications increase the risk of heatstroke, leaving psychiatric patients in jails and prisons at risk.


Nicole Guanci, MD

Latest:

Issues in Treating Patients With Intellectual Disabilities

Psychiatric disorders in persons with intellectual disabilities are typically more severe and more difficult to diagnose than in the general population. Clearly, those who diagnose ID and treat patients with this condition face a number of challenges.


Nicole Kosanke, PhD

Latest:

Beyond Addiction

The authors of this book leave readers feeling empowered, knowing that they can be an important driver of change. It also reminds psychiatrists about some core components of the patient experience.


Nicole M. Lanouette, MD

Latest:

Culture as a Factor in Adherence: Learning From Latino Experiences

Successful culturally adapted interventions to improve adherence among Latino patients with depression and schizophrenia confirm how important it is to understand a patient’s entire sociocultural environment.


Nidal Nabhan Abou, MD

Latest:

Violence, Crime, and Violent Video Games: Is There a Correlation?

What effect does exposure to violence in video games have on behavior? These authors examine the evidence.


Nikole Benders-Hadi, MD

Latest:

Contraception and Misconceptions

Psychiatrists who treat women and adolescent girls may find it necessary to discuss with their patients reproductive planning and the role of contraception in setting comprehensive treatment goals. Here's why.


Nir Lipsman, MD

Latest:

Deep Brain Stimulation in Chronic and Severe Anorexia Nervosa

Deep Brain Stimulation is a neurosurgical procedure initially developed for the management of treatment-refractory movement disorders. More recently, the rationale for the use of DBS in anorexia nervosa derives from several sources.


Niranjan S. Karnik, MD, PhD

Latest:

New Approaches to Juvenile Delinquency: Psychopathology, Development, and Neuroscience

New findings in epidemiology, developmental psychiatry, and neuroscience offer the opportunity for a new perspective on the problems of juvenile delinquency and bring to bear the insights of modern psychiatry in the treatment and successful rehabilitation of juvenile offenders.


Nisha Chhabria, MD

Latest:

Management of Acute Ischemic Stroke: Reviewing the Options

Despite the significant progress in stroke prevention and treatment over the past 10 years, stroke remains the third leading cause of death in the United States.1 Approximately 700,000 strokes occur every year; the majority are ischemic.1 In 1996, the FDA approved the use of intravenous tissue-type plasminogen activator (t-PA).


Noah S. Philip, MD

Latest:

Augmentation Strategies in MDD Therapy

For many patients with depression, full symptom remission remains elusive despite multiple trials of antidepressants. This article focuses on psychopharmacological and related interventions.


Nora D. Volkow, MD

Latest:

New Insights Into the Effects of Alcohol on the Brain

What are the latest findings on acute and chronic effects of alcohol on the human brain?


Norm Alessi, MD

Latest:

Psychiatric Informatics: Exploring Myths and Barriers

Myth #1; I don't need computers in my work. Myth # 2: If I wait, things will stabilize and the prices will come down. Myth # 3: I'm too old to begin thinking about computers. Myth # 4: It's easier for men to understand computers than women.


Norm Straker, MD

Latest:

Dynamic Psychotherapy for Cancer Patients and Their Partners

The estimated number of patients with cancer in this country is 10.5 million. Close to a million and a half are new cases, and it is estimated that 560,000 people die of cancer each year.1 There is clearly a large group of cancer patients and their families at high risk for serious psychiatric illness. In this article, I focus on the advantages of a psychodynamic approach and address how this approach is helpful in the liaison function and psychotherapy of cancer patients and their partners.


Norman B. Levy, MD

Latest:

Clinical Considerations in Renal Failure, Depression, and Delirium

Renal failure is not an uncommon disorder either in the general public or in patients with psychiatric disorders, but accompanying depression, anxiety, and loss must be attended to during such an illness.


Norman E. Rosenthal, MD

Latest:

Botulinum Toxin for Depression? Emotional Proprioception

If larger trials confirm the strong antidepressant effects observed so far, botulinum toxin may become a standard therapeutic addition to the psychiatric armamentarium.


Norra Macready

Latest:

Stroke Complications: Hiding in Plain Sight?

Despite the enormous progress made in stroke diagnosis and treatment in recent years, patients continue to experience stroke-related deficits that clinicians-even those working on stroke rehabilitation units-do not always recognize or record. In a recent study of 53 patients who underwent screening tests within 10 days of admission to a stroke unit, every impaired patient had at least 1 undocumented cognitive or sensory deficit. The authors suggested that without formal testing with standardized assessments, much stroke-related impairment goes unrecognized and perhaps untreated.


Oded Gonen, PhD

Latest:

The Neurochemistry of Pediatric Major Depressive Disorder

Major depressive disorder (MDD) in pediatric populations represents a significant public health concern. Rates of MDD rise dramatically in adolescence, with an estimated lifetime prevalence of 15% in adolescents aged 15 to 18.


Oksana Volshetyn, MD

Latest:

Rehabilitative Management of Complications of Spinal Cord Injury

Predicting extent of neurologic recovery is crucial. The most accurate and standardized method is clinical neurologic examination using the International Standards for Neurological Classification of Spinal Cord Injury.


Ole Bernt Fasmer, MD

Latest:

Are Migraines and Bipolar Disorder Related?

Migraine is characterized by episodes of headache with qualities such as unilateral location, throbbing pain and aggravation by routine physical activity. Additional symptoms include nausea, photophobia and phonophobia. Some patients have aura symptoms, usually visual, before the headache phase (Davidoff, 1995). Prodromal and accompanying symptoms of migraine attacks often are psychiatric in nature, such as depression, elation, irritability, anxiety, overactivity, difficulty thinking, anorexia or increased appetite. In some patients, an organic mental syndrome can be part of a migraine attack (Davidoff, 1995). In other patients, an acute psychotic condition is the dominating clinical feature. This presentation, with paranoid delusions, hallucinations and anxiety, has been described in families with hemiplegic migraine (Spranger et al., 1999). Migraine is, therefore, an important differential diagnosis in relation to episodic phenomena with a mixture of somatic and psychiatric symptoms. In addition, psychosocial stress is the most common precipitating factor for a migraine attack (Davidoff, 1995).

© 2024 MJH Life Sciences

All rights reserved.